Year: 2024
Type: article
Abstract: This review article explores the evolving landscape of Molecular Radiotherapy (MRT), emphasizing Peptide Receptor Radionuclide Therapy (PRRT) for neuroendocrine tumours (NETs). The primary focus is on the transition from β-emitting radiopharmaceuticals to α-emitting agents in PRRT, offering a critical analysis of the radiobiological basis, clinical applications, and ongoing developments in Targeted Alpha Therapy (TAT). Through an extensive literature review, the article delves into the mechanisms and effectiveness of PRRT in targeting somatostatin subtype 2 receptors, highlighting both its successes and limitations. The discussion extends to the emerging paradigm of TAT, underlining its higher potency and specificity with α-particle emissions, which promise enhanced therapeutic efficacy and reduced toxicity. The review critically evaluates preclinical and clinical data, emphasizing the need for standardised dosimetry and a deeper understanding of the dose-response relationship in TAT. The review concludes by underscoring the significant potential of TAT in treating SSTR2-overexpressing cancers, especially in patients refractory to β-PRRT, while also acknowledging the current challenges and the necessity for further research to optimize treatment protocols.
Source: Pharmaceuticals
DOI: 10.3390/ph17030334
Institutions: King's College London, University of Iowa
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,296
Awards: G1188378846, G1319261684, Matrix metalloproteinase activated Multimodal 'Theranostic' Drug Delivery Imaging Agents for thrombosis, G1616352047, G1735243431, G2023265850, G2378433742, G2571995107, G3092906449, G3536743922, G4012832340, G4062541594, G4202347798, Development of novel acyclic chelators for gallium-68 and scandium-44 used in PET, EPSRC Centre for Doctoral Training in Smart Medical Imaging at King's College London and Imperial College London, G4901987235, G5132809365, G5357908696, G5386915326, Alpha-Particle Emitter Peptide Receptor Targeted Radionuclide Therapy for Neuroendocrine Tumors, G5540773720, G557771631, G5671676275, G5883278046, G6452560763, GMP peptide manufacturing, pharmacology/toxicology, and scaled radionuclide production and validation for Pb-212 receptor targeted alpha-particle therapy clinical trials for metastatic melanoma., A "Shake and Use" Theranostic System for Combined Radio-imaging and Photodynamic Therapy, G688199420, Neuroendocrine Tumor Specialized Programs of Research Excellence (SPORE) in Human Cancer, G7343948406, G7555988708, Preclinical pharmacology, toxicology, biodistribution and dosimetry, and radionuclide production CMC validation for Pb-212 receptor targeted alpha-particle therapy for neuroendocrine tumors., G7955567073, G796099640, Image-guided dosimetry-based alpha particle therapy for neuroblastoma., MICA: Radiobiology for effective alpha particle and Auger electron molecular radionuclide therapy in neuroendocrine cancer, G8995088244, G9000089304, G9000296213, G9000352121
OpenAlex ID: W4392377402